BCKDK and renal cell carcinoma: IHC analysis of transplanted tumors revealed that BCKDK, p‐AKT, p‐mTOR, and caspase‐3 expression were significantly downregulated in BCKDK‐deficient tumors (Figure 6M), indicating that targeting BCKDK enhances doxorubicin‐mediated apoptosis and suppresses tumorigenesis in RCC.